ID
32071
Descripción
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of demographics, informed consent and randomization/treatment number. To be filled in at Visit 1. Timing: Day 0 Age: 6 weeks +/- 1 week
Link
https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1
Palabras clave
Versiones (2)
- 16-10-18 16-10-18 - Sarah Riepenhausen
- 16-10-18 16-10-18 - Sarah Riepenhausen
Titular de derechos de autor
GlaxoSmithKline
Subido en
16 oktober 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Demographics and Administrative Data
- StudyEvent: ODM
Similar models
Demographics and Administrative Data
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])